Latest Orphan drugs Stories
SOUTH SAN FRANCISCO, Calif., May 6, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Bank of America Merrill Lynch Health Care Conference on Thursday, May 12, 2011 at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time).
SILVER SPRING, Md., May 6, 2011 /PRNewswire-USNewswire/ -- On Thursday, the U.S.
WESTMINSTER, Colo., May 4, 2011 /PRNewswire/ -- Plato BioPharma, Inc. (PBI) and Gilead Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., April 28, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc.
SAN FRANCISCO, April 21, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc.
A leukemia drug may be used as a new target therapy for some lung cancer patients.
WALTHAM, Mass., March 31, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced 11 posters on entinostat, an oral, highly selective, class I histone deacetylase (HDAC) inhibitor, will be presented at the 102nd Annual American Association for Cancer Research meeting April 2 to April 6 in Orlando, FL.
- Glenmark's first novel molecule for an oncology indication - GBR 401 is a monoclonal antibody targeting CD19.
EMERYVILLE, Calif., March 28, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced its plans to expand the Phase 3 European clinical trial FOCUS, which is evaluating the efficacy and tolerability of carfilzomib, a selective next-generation proteasome inhibitor.
Patients taking imatinib (Gleevec) for CML, or chronic myelogenous leukemia, and in remission after two years of treatment, have a mortality rate similar to that of the general population according to a study published online [date] in the Journal of the National Cancer Institute.
- a meat pie that is usually eaten at Christmas in Quebec